Aurinia’s drug to treat autoimmune kidney disease hits its goals in late-stage trial
Aurinia Pharmaceuticals (AUPH) said Wednesday evening that an experimental medicine used to treat patients with lupus nephritis, an autoimmune kidney disease, achieved all primary and secondary efficacy goals in a late-stage clinical trial.
The drugmaker, headquartered near Vancouver, Canada, expects to submit a marketing application to the U.S. Food and Drug Administration in the first half of next year.
